One of the things that Oncotarget has always done is been able to help people with their cancer treatment options. Mikhail Blagosklonny made Oncotarget so that people could get the research that they needed and so that they would be able to try different things with the options that they had. Since Oncotarget has gotten bigger in the time that they have been helping people for the best cancer treatment, the publication has been able to add more specialists and more options for the specialists so that they will be able to continue their practices while they are helping other people. All of the things that Oncotarget has done have enabled specialists to learn more about their practice and about how treatment can be effective for many different purposes. Oncotarget has even shown oncologists how they will be able to make things better using different methods.
Since Oncotarget first started, it has always been geared toward oncologists. In the beginning, only oncologists were able to do different things with it and they were the only ones who could add research to the things that were going on with the publication. All of that changed when Mikhail Blagosklonny realized that Oncotarget would make more sense with the people who were in other areas of medicine and who had chosen to specialize in the things that they would be able to do for each other. He knew that having these specialists could make everything better and could bring more attention onto Oncotarget so that people could try new things.
Now that more specialists are able to participate in the peer review, they are going to be able to come up with new options for others. This is something that Mikhail Blagosklonny did intend on and something that he wanted to make happen so that other people would have a chance to do more with it. He also wanted to show people that they could try new things in their medical practices. There are now more treatments than ever for cancer thanks to Mikhail Blagosklonny and the alternative options that have been discovered by specialists who participate in Oncotarget.